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AbstrAct
Multiple myeloma (MM) is a hematological malignancy characterized by the 
aberrant accumulation of clonal plasma cells in the bone marrow. Despite recent 
advancement in anti-myeloma treatment, MM remains an incurable disease. This study 
showed higher intrinsic oxidative stress and higher Trx1 and TrxR1 protein levels in 
MM cells compared to normal cells. Drug-induced Trx1 (PX-12) and TrxR1 (Auranofin) 
inhibition disrupted redox homeostasis resulting in ROS-induced apoptosis in MM cells 
and a reduction in clonogenic activity. Knockdown of either Trx1 or TrxR1 reduced 
MM cell viability. Trx1 inhibition by PX-12 sensitized MM cells to undergo apoptosis 
in response to the NF-кβ inhibitors, BAY 11-7082 and curcumin. PX-12 treatment 
decreased the expression of the NF-кβ subunit p65 in MM cells. Bortezomib-resistant 
MM cells contained higher Trx1 protein levels compared to the parental cells and PX-
12 treatment resulted in apoptosis. Thus, increased Trx1 enhances MM cell growth and 
survival and exerts resistance to NF-кβ inhibitors. Therefore inhibiting the thioredoxin 
system may be an effective therapeutic strategy to treat newly diagnosed as well as 
relapsed/refractory MM.
IntroductIon
Multiple myeloma (MM) is a cancer characterized 
by aberrant accumulation of malignant monoclonal 
plasma cells in the bone marrow. MM accounts for 2% 
of all neoplasms and is the second most common form 
of hematological malignancies [1]. There are a number 
of chemotherapeutic agents that are being used as anti-
myeloma therapies, for example, the immunomodulator 
thalidomide [2] and its derivative lenalidomide [3], and 
a proteasome inhibitor bortezomib [4]. Despite such 
advancements in anti-myeloma therapies, MM remains an 
incurable disease with only a slight increase in the median 
survival rate to 5 years [5]. Upon prolonged treatment 
MM cells acquire resistance to the given treatment, and 
thus relapse is inevitable. Therefore, novel therapeutic 
approaches to treat MM are desperately needed. 
Intrinsic oxidative stress is a hallmark of cancer that 
give rise to the conditions leading to tumor development 
and progression [6]. In response to increased reactive 
oxygen species (ROS) levels and their toxic effects, cells 
have evolved a number of survival pathways, which 
includes the expression of antioxidant molecules and 
stress-response molecules. However, cancer cells exploit 
this advantage and adapt to the enhanced oxidative stress 
through an increased antioxidant capacity. Cancer cells 
with higher intrinsic oxidative stress are more resistant 
to the disruption of redox regulation compared to non-
cancerous cells [7].
The thioredoxin (Trx) system is one of the major 
antioxidant systems that maintain the intracellular 
redox homeostasis [8]. The Trx system is comprised of 
thioredoxin 1 (Trx1), a cellular redox protein, thioredoxin 
reductase 1 (TrxR1) enzyme, and NADPH. The Trx 
system maintains cellular redox homeostasis by either 
directly scavenging ROS [9] or by regulating several 
redox enzymes [10, 11]. In addition, Trx1 also regulates 
various redox-sensitive transcription factors by acting as 
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a co-factor to reduce specific cysteine residues [12, 13]. 
Trx1 also acts as a growth factor that stimulates cancer cell 
proliferation and tumor growth and inhibits spontaneous 
and drug-induced apoptosis [14]. Expression of Trx1 is 
upregulated in many human cancer types, correlating with 
cancer cell proliferation, survival, and chemoresistance 
[15-17]. Similarly, expression and activity of TrxR is 
upregulated in many human cancer types [15, 18] and its 
inhibition results in cancer cell apoptosis [19]. However, 
there are no previous reports on the physiological and 
therapeutic significance of the Trx family members in MM 
and its survival.
Nuclear factor-кβ (NF-кβ) is a nuclear transcription 
factor regulating the expression of various genes involved 
in cell proliferation, tumorigenesis, and inflammation. 
The NF-кβ family is comprised of five members 
including p50/p105 (NF-кβ1), p52/p100 (NF-кβ2), p65 
(Rel A), c-Rel, and Rel B [20]. Under non-stimulating 
conditions, NF-кβ binds a class of inhibitor proteins 
called Inhibitor of кβ (Iкβ) [20]. Upon stimulation, Iкβ 
undergoes phosphorylation and subsequent degradation by 
the proteasome releasing NF-кβ, which then translocates 
into the nucleus where it activates gene expression [21]. 
NF-кβ and its signaling pathways are constitutively 
activated in MM cell lines as well as in patient myeloma 
cells [22] and constitutive NF-кβ activity is required for 
the pathogenesis of MM [23, 24]. While the proteasome 
inhibitor bortezomib inhibits NF-кβ signaling by 
preventing the degradation of Iкβ, resulting in MM cell 
apoptosis [25, 26], and significant improvement in terms 
of disease control and patient survival [4, 27], upon 
prolonged treatment myeloma cells become resistant to 
bortezomib [28]. 
Being a critical redox regulator, Trx1 activates 
several redox sensitive transcription factors including NF-
кβ. Under oxidative stress conditions, Trx1 increases the 
DNA binding activity of NF-кβ subunits, enhancing NF-
кβ mediated gene expression leading to cell proliferation 
and survival [29]. However, not much is known about the 
interaction between Trx1 and the NF-кβ pathway in MM 
cells.
The present study was designed to characterize the 
role of Trx1 and TrxR1 in myeloma cell survival, growth, 
and chemo-resistance. Our results show that higher Trx1 
and TrxR1 expression levels correlate with myeloma 
cell survival and growth, and protect MM cells against 
increased intrinsic oxidative stress. Trx1 and TrxR1 
inhibition results in ROS-induced apoptosis in MM cells. 
Our data also demonstrate that inhibition of Trx1 using a 
sub-lethal concentration of PX-12 sensitizes MM cells to 
undergo cell death in response to NF-кβ inhibition. Results 
show that Trx1 inhibition decreases levels of the NF-кβ 
subunit p65 protein in MM cells. Moreover, the Trx1 
inhibiting drug PX-12 induces apoptosis of bortezomib-
resistant MM cells. Thus, Trx1 may be an effective 
therapeutic target either alone or in combination with 
other NF-кβ targeted therapies in the treatment of newly 
diagnosed as well as relapse/refractory MM patients.
results
Multiple myeloma cells have higher intrinsic 
oxidative stress and an up-regulated thioredoxin 
system
Increased oxidative stress is a hallmark of many 
human cancer types, which leads to aberrant cancer growth 
and proliferation [6]. The levels of intrinsic oxidative 
stress were examined in MM cell lines (RPMI8226, U266) 
and normal peripheral blood mononuclear cells (PBMCs) 
by analyzing the intracellular ROS levels. Both MM cell 
lines have significantly higher ROS levels compared to 
PBMCs (Figure 1A). 
To examine whether MM cells have increased 
antioxidant capacity, we first evaluated the expression 
levels of Trx1 and TrxR1 in myeloma cells compared to 
PBMCs. A gene expression omnibus dataset (GSE6477) 
shows that both Trx1 (Figure 1B) and TrxR1 (Figure 1C) 
are expressed at significantly higher levels in new and 
relapsed myeloma patient cells compared to normal cells. 
Western blot analysis confirmed higher protein levels of 
Trx1 (Figure 1D) and TrxR1 (Figure 1E) in MM cell lines 
compared to PBMCs. 
trx1 and trxr1 inhibition reduces MM cell 
proliferation and viability
To study the role of Trx1 and TrxR1 in the growth 
and survival of MM cells, we used both chemical 
inhibition and a knockdown approach. Auranofin reacts 
with selenol-containing residues present in TrxR1, inhibits 
its activity [30], and shows excellent anti-tumor activity 
[19]. PX-12 inhibits Trx1 by irreversibly alkylating the 
Cys73 residue [31] and has been shown to exert anti-tumor 
activity [32, 33]. We used PX-12 and auranofin as tools 
to study the cytoprotective functions of Trx1 and TrxR1 
in MM cells. Treatment of RPMI8226, U266, and control 
PBMCs with increasing concentrations of PX-12 (0-40 
µM) (Figure 2A) and auranofin (0-8 µM) (Figure 2B) for 
24 hours resulted in a marked inhibition of RPMI8226 and 
U266 cell proliferation compared to PBMCs. 
To ascertain if specific knock-down of Trx1 and 
TrxR1 could reproduce the effect of drug-induced Trx1 
and TrxR1 inhibition on MM growth, we used the Trx1-
antisense (Trx1-AS) plasmid DNA and TrxR1 specific 
siRNA. Transfection of the Trx1-antisense plasmid 
decreased Trx1 protein levels compared to the control 
vector (Figure 2C and 2E) and reduced RPMI8226 (Figure 
2D) and U266 (Figure 2F) cell viability by 50% after 2 
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and 3 days of incubation, respectively. Similarly, siRNA 
against TrxR1 suppressed TrxR1 protein expression 
compared to the control siRNA (Figure 2G and 2I) and 
reduced RPMI8226 (Figure 2H) and U266 (Figure 2J) cell 
viability by approximately 30-50% after 2 and 3 days of 
incubation, respectively. 
Inhibition of trx1 or trxr1 decreases the 
clonogenic activity of MM cells
Myeloma cells have clonogenic activity and these 
clonogenic myeloma cells are resistant to a number of 
clinically used anti-myeloma drugs [34]. We investigated 
whether inhibiting either Trx1 or TrxR1 reduces 
clonogenic activity of myeloma cells. A significant 
reduction in the number of colonies was observed at 10 
µM PX-12 in RPMI8226 (Figure 3A and 3E) and 5 µM 
PX-12 in U266 (Figure 3B and 3E). Similarly, 4 µM 
auranofin treatment significantly decreased the number of 
colonies in both MM cell lines (Figure 3C, 3D and 3F). 
No colonies were observed in MM cells treated with 8 
µM auranofin. No significant effect on colony number was 
observed with lower concentrations of PX-12 or auranofin 
(data not shown). 
Inhibition of trx1 or trxr1 induces MM cell 
apoptosis
Next we determined the mode of myeloma cell 
death in response to Trx1 and TrxR1 inhibition using 
Figure 1: Multiple myeloma cells have higher intrinsic oxidative stress and an upregulated thioredoxin system. A. Basal 
ROS levels were measured in myeloma cell lines (RPMI8226, U266) and two samples of control PBMCs using H2DCFDA. Values indicate 
mean ± SEM of three independent experiments performed in triplicate. One-way ANOVA followed by Tukey’s post-test were employed. 
*, P < 0.05 (compared to PBMCs) b. c. Expression of Trx1 and TrxR1 in patient myeloma cells (new MM and relapsed) and normal cells 
were determined from the gene expression profile arrays deposited in the gene expression omnibus database (GSE6477). One-way ANOVA 
followed by Tukey’s post-test was performed. P < 0.001 (Trx1) and P < 0.05 (TrxR1) compared to normal cells. d. e. Whole cell extracts 
were prepared from myeloma cell lines (RPMI8226, U266) and control PBMCs, and Western blot analysis was conducted for Trx1 d. and 
TrxR1 e. protein levels. β-tubulin was used to confirm the equal loading. Western blots are representative of three independent experiments.
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Figure 2: Inhibition of trx1 and trxr1 reduces myeloma cell proliferation and viability. A. b. RPMI 8226, U266, and 
control PBMCs were treated with indicated concentrations of PX-12 A. and auranofin B. for 24 hours. Cell proliferation was assessed by 
MTT assays. Values indicate mean ± SEM of three independent experiments performed in triplicate. c. d. e. F. RPMI8226 c. d. and U266 
e. F. cells were transfected with 2 µg of pcDNA 3.1 vector or Trx1-AS plasmid. Trx1 protein levels (24 hours) were analyzed by western 
blot in RPMI8226 c. and U266 e.. β-tubulin was used as a loading control. Cell viability was measured at the indicated time points by using 
Trypan blue exclusion method in RPMI8226 d. and U266 F.. G. H. I. J. RPMI8226 G. H. and U266 I. J. cells were transfected 30 nmol/L 
of either control or TrxR1 specific siRNA. TrxR1 protein levels (48 hours) were analyzed by western blot in RPMI8226 G. and U266 I.. 
β-tubulin was used as a loading control. Cell viability was measured at the indicated time points by using the Trypan blue exclusion method 
in RPMI8226 H. and U266 J.. Values indicate mean ± SEM (n = 3). Two-way ANOVA followed by Sidak’s post-test was employed. *, P 
< 0.05
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specific inhibitors. RPMI8226, U266, and control PBMCs 
were treated with PX-12 (0-20 µM) and auranofin (0-4 
µM) for 24 hours and caspase-3 activity was measured. 
5 µM PX-12 significantly increased caspase-3 activity by 
3-fold in RPMI8226 and 4-fold in U266 cells compared to 
non-treated cells (Figure 4A). Similarly, 2 µM auranofin 
significantly increased caspase-3 activity by 2.5-fold 
in RPMI8226 and 2.3-fold in U266 cells compared to 
non-treated cells (Figure 4B). No significant increase in 
caspase-3 activity was observed in PX-12 and auranofin-
treated control PBMCs. 
Inhibition of the trx system results in ros-
induced apoptosis in MM
We next investigated the role of Trx1 and TrxR1 
in protecting MM cells against higher intrinsic oxidative 
stress and whether their inhibition disrupts intracellular 
redox homeostasis in myeloma cells. Treatment of 
Figure 3: Inhibition of trx1 or trxr1 decreases clonogenic activity of MM cells. A. b. Methylcellulose colony formation 
assay of RPMI8226 A. and U266 b. cells treated with 5 µM and 10 µM PX-12. c. d. Methylcellulose colony formation assay of RPMI8226 
c. and U266 d. cells treated with 4 µM and 8 µM auranofin. e. Number of colonies formed after PX-12 treatment of RPMI8226 and 
U266 cells. F, Number of colonies formed after auranofin treatment of RPMI8226 and U266 cells. Values indicate mean ± SEM of three 
independent experiments performed in duplicate. One-way ANOVA followed by Tukey’s post-test was employed. * (U266), # (RPMI8226), 
P < 0.05
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RPMI8226 and U266 cells with PX-12 (0-20 µM) for 
24 hours showed a significant increase in the amount of 
ROS at 5 µM PX-12 as indicated by H2DCFDA oxidation 
(Figure 5A). To investigate the involvement of ROS, we 
analyzed whether two antioxidants, N-acetyl cysteine 
(NAC) and ascorbic acid, protected MM cells against 
PX-12-induced apoptosis. Treatment of both cell lines 
with 5 µM PX-12, with or without 5 mM NAC, showed 
that addition of NAC significantly abrogated the PX-12-
induced increase in ROS in both MM cell lines (Figure 
S1). These results confirmed that Trx1 inhibition by PX-
12 increases intracellular ROS levels in MM. Moreover, 
treatment of cells with NAC (5 mM) together with PX-12 
(5 µM) significantly rescued MM cells from undergoing 
cell death (Figure 5B) and also abrogated PX-12-induced 
apoptosis in both myeloma cell lines (Figure 5C). Ascorbic 
acid (AA) showed a similar protective effect, but was not 
as effective as NAC (Figure S2).
We then investigated the effect of auranofin on 
the intracellular ROS levels in MM cells. Treatment 
of RPMI8226 and U266 cells with auranofin (0-4 µM) 
significantly increased intracellular ROS levels in both 
MM cell lines (Figure 5D). In addition, addition of 5 
mM NAC to auranofin-treated RPMI8226 and U266 
cells significantly rescued them from undergoing cell 
death (Figure 5E) and apoptosis (Figure 5F). Addition of 
ascorbic acid also showed a similar protective effect, but 
was observed to be less effective than NAC (Figure S2). 
trx1 inhibition sensitizes myeloma cells to nF-
кβ inhibitors and decreases NF-кβ p65 protein 
expression 
Since MM cells have high NF-кβ activity, we 
tested the effect of the NF-кβ inhibitors, BAY 11-7082 
[35] and curcumin [36], on MM cell proliferation using 
MTT assays. BAY 11-7082 had no effect on RPMI8226 
cell proliferation, whereas U266 cell proliferation was 
inhibited only at a higher concentration (10 µM) (Figure 
6A). Curcumin reduced RPMI8226 and U266 cell 
proliferation only at higher concentrations (10 µM and 20 
µM) (Figure S3A). Our results also showed an increase 
in Trx1 protein levels in BAY 11-7082-treated RPMI8226 
and U266 cells (Figure S4). Thus, increased Trx1 levels 
may be responsible for the decreased sensitivity of MM 
cells to NF-кβ inhibitors.
We then aimed to investigate the role of Trx1 
in the resistance of MM cells to NF-кβ inhibitors. 
RPMI8226 and U266 cells were treated with a sub-lethal 
Figure 4: Inhibition of trx1 or trxr1 induces MM cell apoptosis. A. b. RPMI8226, U266, and control PBMCs were treated 
with indicated concentrations of PX-12 A. and auranofin b. for 24 hours. Caspase-3 activity in treated and untreated myeloma cell lines and 
PBMCs was measured by monitoring the cleavage of Ac-DEVD-AMC. Values indicate mean ± SEM (n = 3). One-way ANOVA followed 
by Tukey’s post-test was employed. * (U266), # (RPMI 8226), P < 0.0001
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concentration of PX-12 (2.5 µM), with or without 5 µM 
BAY 11-7082, for 24 hours. Treatment with either PX-12 
or BAY 11-7082 alone had no effect on cell proliferation. 
However, co-treatment of MM cells with both PX-12 and 
BAY 11-7082 significantly reduced RPMI8226 and U266 
cell proliferation by 80% (Figure 6B). We then measured 
apoptosis in RPMI8226 and U266 cells treated with either 
PX-12 or BAY 11-7082 alone or in combination, which 
showed a significant increase in caspase-3 activity (Figure 
6C) when cells were treated with PX-12 and BAY 11-7082 
together. To confirm the results observed with PX-12, 
we used Trx1 knockdown using the Trx1-AS plasmid in 
combination with BAY 11-7082, which reduced U266 cell 
proliferation (Figure 6D). Similarly, treatment with either 
PX-12 or 5 µM curcumin alone had no effect on MM cell 
proliferation, but co-treatment with PX-12 and curcumin 
significantly reduced RPMI8226 and U266 proliferation 
by 40-45% (Figure S3B). Co-treatment with PX-12 and 
curcumin also significantly increased caspase-3 activity 
in RPMI8226 and U266 cells compared to treatment with 
either PX-12 or curcumin alone (Figure S3C). 
Trx1 enhances the DNA biding activity of NF-кβ 
subunit p50 by reducing a cysteine at position 62 [29]. 
Based on this information, we investigated the effect of 
Trx1 inhibition on the expression and localization of NF-
кβ subunit p65 in MM cells. Western blot results showed 
that PX-12 treatment significantly decreased cellular 
p65 protein levels, including in the nuclear and cytosolic 
fractions, in a concentration dependent manner in both 
MM cell lines (Figure 6E). 
Figure 5: Inhibition of Trx system results in ROS-induced apoptosis in MM. A. RPMI8226 and U266 cells were treated 
with indicated concentrations of PX-12 for 24 hours and then assessed for H2DCFDA oxidation. b. c. RPMI8226 and U266 cells were 
treated with 5 µM PX-12 alone or in combination with 5 mM NAC for 24 hours followed by measuring cell viability using Trypan blue 
exclusion b., and examination of apoptosis by measuring Caspase-3 activity c.. d. RPMI8226 and U266 cells were treated with indicated 
concentrations of auranofin for 24 hours and then assessed for H2DCFDA oxidation. e. F. RPMI8226 and U266 cells were treated with 2 
µM auranofin alone or in combination with 5 mM NAC for 24 hours followed by measuring cell viability using Trypan blue exclusion e. 
and examination of apoptosis by measuring caspase-3 activity F.. One-way ANOVA followed by Tukey’s post-test was employed. *, P < 
0.05. Values indicate mean ± SEM of three independent experiments performed in triplicate. For caspase-3 activity assay (n = 3).
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Figure 6: Trx1 inhibition sensitizes myeloma cells to NF-кβ inhibitors and decreases NF-кβ p65 protein expression. 
A. RPMI8226 and U266 cells were treated with indicated concentrations of BAY 11-7082 for 24 hours and cell proliferation was assessed 
by MTT assays. b. c. RPMI8226 and U266 cells were treated with 2.5 µM PX-12 and 5 µM BAY 11-7082 alone or in combination for 24 
hours and cell proliferation b. and caspase-3 activity were measured c.. d. U266 cells were transfected with Trx1-AS plasmid and pcDNA 
3.1. 24 hours after transfections, cells were treated with or without 5 µM BAY 11-7082 for 24 hours and cell proliferation was assessed 
by MTT. Values indicated mean ± SEM of three independent experiments performed in triplicate. For caspase-3 activity assay (n = 3). 
One-way ANOVA followed by Tukey’s post-test was employed. *, P < 0.05 (Compared to different treatment groups) e. RPMI8226 and 
U266 cells were treated with PX-12 (0-20 µM) for 24 hours. Nuclear, cytosolic, and total protein extracts were prepared and p65 protein 
expression was analyzed by western blot analysis. Lamin B1 (nuclear fractions) and β-tubulin (cytosolic fractions and total protein lysates) 
were used as loading controls. Western blots are the representative of three independent experiments.
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Inhibition of trx1 reduces proliferation and 
induces apoptosis of bortezomib-resistant MM 
cells
As MM cells acquire resistance to the bortezomib 
upon prolonged treatment resulting in disease relapse, 
we evaluated the effect of Trx1 inhibition on the growth 
and survival of drug-resistant myeloma cells. We first 
generated a bortezomib-resistant (BR) cell line (U266-BR) 
from the highly-sensitive parental U266 cell line (Figure 
7A). Trx1 protein levels were observed to be higher in 
U266-BR cells compared to the U266 cells (Figure 7B). 
We next examined the effect of Trx1 inhibition on the 
survival of U266-BR cells. Treatment of U266-BR cells 
with PX-12 for 24 hours significantly inhibited their 
proliferation (Figure 7C). Moreover, PX-12 also increased 
caspase-3 activity in U266-BR cells indicating that cells 
have undergone apoptosis (Figure 7D). 
dIscussIon
Despite the development of many anti-myeloma 
therapies, to date MM remains an incurable plasma cell 
malignancy [2-4] with drug resistance resulting in disease 
relapse. Therefore, development of new anti-myeloma 
therapies and strategies to treat drug-resistant MM patients 
is desperately needed. Many of the currently available 
anticancer drugs, including bortezomib, the most effective 
anti-myeloma drug, induce apoptosis by increasing the 
intracellular ROS levels and oxidative stress [37, 38]. 
However, cancer cells enhance their antioxidant capacity 
in response to increased oxidative stress to escape the 
toxic effect of drugs. Therefore, therapies that inhibit the 
activity of antioxidants to disrupt redox homeostasis may 
provide a more effective anti-myeloma therapy. 
The role of redox proteins, Trx1 and TrxR1, in MM 
pathogenesis is largely unknown. Here, for the first time, 
we reported the cytoprotective role of Trx1 and TrxR1 in 
MM, and showed that disruption of intracellular redox 
homeostasis by inhibiting either Trx1 or TrxR1 reduces 
Figure 7: Inhibition of trx1 reduces proliferation and induces apoptosis in bortezomib-resistant MM cells. A. 
Parent-U266 and U266-BR cells were treated with bortezomib for 24 hours and cell proliferation was assessed by MTT assay. b. Trx1 
protein expression in U266 and U266-BR cells was analyzed by western blot. β-tubulin was used as a loading control. c. d. U266-BR 
cells were treated with indicated concentrations of PX-12 for 24 hours. Cell proliferation was assessed by MTT assay c. and apoptosis was 
assessed by measuring caspase-3 activity d.. Values indicate mean ± SEM of three independent experiments performed in triplicate. For 
caspase-3 activity assay (n = 3). One-way ANOVA followed by Tukey’s post-test was employed. *, P < 0.0001 (Compared to the control) 
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MM cell growth and survival. Our data showed that MM 
cells have higher intracellular ROS levels and increased 
Trx1 and TrxR1 expression levels compared to the normal 
PBMCs (Figure 1). We hypothesized that high Trx1 and 
TrxR1 protein levels may provide protection against 
increased oxidative stress and leads to MM cell survival 
and growth. As discussed earlier, PX-12 is an irreversible 
inhibitor of Trx1 and has been shown to inhibit tumor 
growth and lead to ROS-induced apoptosis in a variety 
of human cancers including acute myeloid leukemia [32], 
colorectal cancer [39], and lung cancer [33, 40]. PX-12 
has been tested in two independent clinical studies, one in 
advanced gastrointestinal cancer and another in patients 
with advanced pancreatic cancer [41, 42]. Although no 
significant anti-tumor activity of PX-12 was observed in 
both clinical studies, the Trx1 pathway was suggested as an 
effective therapeutic target in cancer. Auranofin, a TrxR1 
inhibitor, leads to oxidative stress-induced lethality and 
apoptosis in cancers including chronic myeloid leukemia 
[19], chronic lymphocytic leukemia [43], prostate 
cancer [44], breast cancer [45], and acute leukemia [46]. 
Auranofin is currently in a phase II clinical trial for 
chronic lymphocytic leukemia and adenosquamous cell 
lung cancer patients. Because of the well documented 
anti-tumor activity of PX-12 and auranofin, we used these 
drugs, along with knockdown of Trx1 and TrxR1, as tools 
to study the cytoprotective role of Trx1 and TrxR1 in MM. 
In line with other studies reporting the cytoprotective role 
of Trx1 and TrxR1 [17, 47], we showed that both drug-
induced inhibition and specific knockdown of Trx1 and 
TrxR1 reduced MM cell proliferation, induced cell death, 
and apoptosis (Figures 2 and 4). Inhibition of Trx1 and 
TrxR1 using PX-12 and auranofin, respectively, had little 
or no cytotoxic effect on non-cancerous PBMCs isolated 
from healthy individuals (Figures 2 and 4). Hence, our 
study suggests that both Trx1 and TrxR1 can be used as 
effective therapeutic targets to treat MM.
The Trx system maintains the intracellular 
redox homeostasis by scavenging ROS and regulating 
various redox enzymes [9-11]. Inhibition of the Trx 
system increases intracellular oxidative stress [48, 49]. 
We showed that Trx1 and TrxR1 inhibition increased 
intracellular ROS levels and induced MM cell apoptosis 
(Figures 3 and 5). Treatment of cells with antioxidants, 
such as NAC or ascorbic acid, has reduced the amount of 
ROS generated in response to Trx inhibition, and rescued 
cells from undergoing apoptosis. 
Overexpression of Trx1 and TrxR1 has been linked 
to the aggressive phenotype of many cancer types, 
including aggressive invasive mammary carcinomas and 
advanced malignant melanoma [15]. Trx1 overexpression 
has been shown to promote breast cancer cell invasion 
by stimulating MMP-9 expression. Inhibition of Trx1 
activity has been shown to decrease MMP-9 expression 
via suppression of NF-кβ activity and expression of NF-
кβ subunits, p50 and p65, in breast cancer cells [50]. 
We showed that inhibition of Trx1 resulted in decreased 
protein levels of NF-κβ subunit p65 in MM cells. 
Moreover, Trx1 inhibition has been shown to reduce the 
clonogenic activity in diffuse large B-cell lymphoma 
[17]. Our findings showed that drugs inhibiting either 
Trx1 or TrxR1 decreased the clonogenic activity in MM 
cells. Interestingly, cells treated with 10 µM PX-12 
resulted in the formation of larger colonies compared to 
the non-treated cells, although 10 µM PX-12 treatment 
reduced the number of colonies in both cell lines. MM 
cell lines, including RPMI8226 and U266, and primary 
MM tumor cells have been shown to possess a small side 
population (SP) of the cells that exhibit more clonogenic 
and tumorigenic capacity [51]. These SP cells possess 
stem cell-like features and express high levels of ABC 
transporter family (ABCB1 and ABCG2), which are 
responsible for SP cell’s drug-resistance [34, 52-54]. 
Moreover, these SP cells have more clonogenic potential 
and the colonies formed by SP cells are larger than the 
colonies formed by non-SP cells [51, 55]. Based on 
this information, we postulated that the larger colonies 
observed in the samples treated with 10 µM PX-12 may 
have formed from the SP cells present in RPMI8226 and 
U266 cells, which may be resistant to PX-12. Thus, an 
upregulated Trx system is linked not just to cancer cell 
proliferation, invasion, metastasis, but also to clonogenic 
activity. 
This study, for the first time, highlights the 
cytoprotective role of Trx1 in the resistance of MM cells 
to NF-кβ inhibitors. We showed that Trx1-inhibited MM 
cells become more sensitive towards the NF-кβ inhibitors 
BAY 11-7082 and curcumin. BAY 11-7082 had no effect 
on RPMI8226 cell growth at any concentrations, while 
only higher concentrations of BAY 11-7082 reduced 
U266 cell growth (Figure 6), and Trx1 protein levels 
were markedly increased in response to BAY 11-7082 
treatment in both MM cell lines. Similarly, only higher 
concentrations of curcumin reduced RPMI8226 and U266 
cell proliferation (Figure S3). Elevated levels of Trx1 
have been implicated in the resistance of cancer cells 
to several chemotherapeutic agents including cisplatin, 
docetaxel, and doxycycline [16, 56]. Inhibition of Trx1 
has been shown to reverse the drug-resistance in many 
cancer types [17]. We hypothesized that high levels of 
Trx1 observed in myeloma cells may exert cytoprotection 
against NF-кβ inhibitors. Our data showed that inhibition 
of Trx1 using a sub-lethal concentration of PX-12 (2.5 
µM) sensitized MM cells to undergo apoptosis in response 
to BAY 11-7082 (Figure 6) or curcumin (Figure S3). The 
amount of cell death and caspase-3 activity was higher in 
cells treated with PX-12 and BAY 11-7082 or curcumin 
together compared to the treatment with either PX-12 or 
BAY 11-7082 or curcumin alone. Specific knockdown of 
Trx1 using the antisense Trx1 plasmid produced similar 
results (Figure 6). Thus, Trx1 inhibition sensitized MM 
cells to NF-кβ inhibitors suggesting that increased Trx1 
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levels may be responsible for the resistance of MM cells 
to NF-кβ-targeted therapies. In addition, we showed that 
Trx1 inhibition resulted in decreased protein levels of NF-
кβ subunit p65 in MM cells. Therefore inhibiting Trx1 in 
conjunction with the NF-кβ pathway may lead to a better 
anti-myeloma therapy. 
In recent years, many anti-myeloma drugs, 
including bortezomib, thalidomide, and dexamethasone, 
have been developed [57, 58]. Bortezomib, a proteasome 
inhibitor, has been shown to inhibit proliferation and 
induce apoptosis of human MM cell lines and primary 
MM patient cells, without any significant cytotoxic 
effect on non-cancerous PBMCs [59]. Upon prolonged 
treatment with these drugs MM cells acquire resistance, 
resulting in relapse [28, 60]. This study highlighted a 
novel strategy to treat drug-resistant MM by inhibiting 
Trx1. We showed that the Trx1 inhibiting drug PX-12 
induced apoptosis in bortezomib-resistant MM cells. 
These bortezomib-resistant U266 cells had higher Trx1 
protein levels compared to the parent U266 cells (Figure 
7B). In line with other studies indicating the role of Trx1 
in chemoresistance [16, 17, 56], our results showed that 
Trx1 inhibition sensitized bortezomib-resistant U266 
cells to undergo apoptosis (Figure 7D). Our findings 
complement a study that showed that inhibition of another 
major antioxidant system, the glutathione system, strongly 
enhances bortezomib-toxicity in MM [61]. Inhibition of 
Trx1, might not only offer a novel approach to treat newly 
diagnosed MM patients, but also those with drug-resistant 
relapsed/refractory MM. 
In conclusion, this research confirms that Trx1 
inhibition results in ROS-induced apoptosis in MM cells, 
sensitizes MM cells to the NF-кβ inhibitors, and also 
induces apoptosis in bortezomib-resistant myeloma cells. 
Thus, Trx1 may be an effective therapeutic target to treat 
newly diagnosed and relapsed/refractory MM patients. 
This research provides an important insight into the 
cytoprotective role of Trx1 and TrxR1 in MM cell survival 
and growth, which may lead to the development of new, 
more effective approaches to treat MM, which is currently 
incurable. This study recommends considering Trx1 and 
TrxR1 as molecular targets for inhibition, which holds 
promising anti-myeloma therapy.
MAterIAls And MetHods
cells and reagents
Human multiple myeloma cell lines (RPMI8226, 
U266) were obtained from Dr. Slavica Vuckovic (QIMR 
Berghofer Medical Research Institute). Human peripheral 
blood mononuclear cells (PBMCs) were isolated from 
the whole blood of healthy volunteers and were collected 
under the ethical approval BPS/08/14/HREC. The cells 
were cultured in RPMI-1640 medium (Gibco, VIC, 
Australia) containing 10% (V/V) fetal bovine serum 
(FBS) (Gibco), 200 mM L-glutamine (Invitrogen, 
VIC, Australia), and 100 U/ml penicillin and 100 µg/
ml streptomycin (Invitrogen). The Trx1 antibody (5G8) 
is a mouse monoclonal antibody generated against 
recombinant human thioredoxin [62]. The monoclonal 
anti-TrxR1 antibody was purchased from R&D systems 
(MN, USA). The polyclonal anti-NF-кβ p65 antibody was 
purchased from GeneTex (CA, USA) and anti-β-tubulin 
antibody was purchased from Abcam. The Trx1 inhibitor 
PX-12 (1-methylpropyl 2-imidazolyl disulfide) was 
purchased from Cayman Chemicals (MI, USA). The NF-
κβ inhibitors BAY 11-7082 and curcumin were purchased 
from Cayman Chemicals and Sigma. The TrxR1 validated 
small interfering RNA (siRNA) and control siRNA were 
purchased from Santa Cruz Biotechnology (TX, USA). 
The Trx1-anti sense plasmid was made by reversing the 
orientation of the Trx insert in pcDNA3.1 (Invitrogen) of 
a pTrx-WT plasmid previously described [63].
database
Gene expression data was obtained from the gene 
expression profile arrays in patient myeloma cells at 
different stages of the disease and healthy cells deposited 
in the gene expression omnibus database GSE6477.
Western blot analysis
Western blot analysis was performed as described 
previously [62]. Whole cell extracts were prepared 
using 0.5% (v/v) Nonidet-40 cell lysis buffer. Nuclear 
and cytosolic fractions were prepared using Nuclear 
Protein Extraction Kit (Cayman Chemicals) according 
to the manufacturer’s guidelines. Protein samples were 
solubilized with 5% SDS (w/v) sample buffer and 
electrophoresed on polyacrylamide gel. Proteins were 
transferred onto a polyvinylidene difluoride membrane 
and were probed with various specific antibodies (Trx1, 
TrxR1, p65, β-tubulin) and the appropriate horseradish 
peroxide-conjugated secondary antibodies. 
Measurement of intracellular ros generation
A dicholorofluorescein (DCF) assay was used to 
determine cellular ROS generation in MM cells and 
control PBMCs as described previously [64]. Briefly, 
either 1 X 106 or 1 X 105 of treated or untreated cells were 
washed with PBS and incubated with 10 µM H2DCFDA 
(Molecular probes, CA, USA), a redox sensitive cell 
permeable dye, for 15 minutes. Cells were then transferred 
to black-walled clear-bottom 96-wells plate in triplicate 
and assessed for H2DCFDA oxidation using a SpectraMax 
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fluorescence plate reader (Molecular Devices). Data were 
analyzed using SoftMax Pro software (Bio-strategy). 
The fluorescence intensity measuring the oxidation of 
H2DCFDA by ROS represents the amount of intracellular 
ROS generation.
cell proliferation assay 
RPMI8226, U266, and PBMCs (0.5 X 106 cells 
per well of 24-wells plate) were treated with appropriate 
inhibitors for 24 hours. After which, cell proliferation was 
determined using MTT solution (Sigma, NSW, Australia). 
cell viability measurement
Cell viability was measured by the Trypan blue 
exclusion method. Treated and untreated cells were stained 
with Trypan blue and viable cells were counted using an 
inverted light microscope.
caspase-3 activity assay
Caspase-3 activity within the treated and untreated 
MM cell lines and PBMCs was determined as described 
previously following the cleavage of Ac-DEVD-AMC 
(Enzo Life Sciences, NY, USA), a caspase-3 substrate 
[65]. Briefly, treated or untreated cells (0.5 X 106 cells) 
were pelleted, washed with PBS, re-suspended in 10-15 
µl of PBS, and transferred to black-walled 96-wells plate. 
90 µl of caspase assay buffer (5 mM dithiothreitol, 100 
mM HEPES, 10% (w/v) sucrose, 0.1% NP-40 at pH 7.25) 
containing 50 μM Ac-DEVD-AMC was added to the 
samples and the amount of AMC cleaved by caspase-3 
was measured at 37°C by measuring the fluorescence at 
excitation wavelength of 370 nm and emission of 445 nm 
using SpectraMax plate reader.
transient transfections
Cells (1.5 X 106 per well) were transfected using 
Amaxa Nucleofector (T-001 program) using equivalent 
molar concentrations of siRNAs (final concentrations of 
30 nmol/L). Empty vector, pcDNA 3.1, and Trx1-anti 
sense plasmids (2 µg) were transfected using the same 
protocol. Transfected cells were incubated for 24 hours 
before the indicated treatments.
establishment of bortezomib-resistant cell lines
Bortezomib-resistant (BR) MM cell line (U266-BR) 
was generated from a parental cell line (U266) by multistep 
exposure of the cells to increasing doses of bortezomib (40 
nM) for 12 weeks. Briefly, cells were initially cultured in a 
low drug concentration for 1 week followed by 1 week in 
a drug-free medium for stabilization. Cells were exposed 
to increasing concentrations of bortezomib for 1 week 
followed by 1 week in a drug-free medium before the next 
bortezomib exposure for 12 weeks, and subsequently cells 
became resistant to bortezomib. The resistant cells were 
expanded in a drug-free medium. Cells were tested for 
drug resistance before any further studies.
Methylcellulose clonogenic assay
The colony formation assay in methylcellulose 
(R&D systems) was performed according to the 
manufacturer’s instructions. Briefly, treated and untreated 
MM cells were plated at the density of 1000 cells/ml in 
1.1ml volume in 35 mm petri dishes. Each plate contained 
RPMI-1640 media consisting of 1.4% methylcellulose, 
25% (v/v) FBS, 100 U/ml penicillin and 100 µg/ml 
streptomycin, and 1% (w/v) BSA. Plates were incubated 
at 37oC, 5% CO2 for 8-10 days. To observe colonies, 
cells were stained with 0.5 mg/ml MTT (Sigma), 500 µl/
plate [66]. After incubating the plates for 1 hour at 37oC, 
colonies containing more than 30 cells were counted using 
an inverted light microscope. Colonies were photographed 
using a Tucsen ix30 camera and TSview software (Tucsen, 
China). 
statistical analysis
All values are presented as mean ± SEM. Data 
was analyzed using the software GraphPad Prism 6 
(GraphPad Software, CA, USA). Statistical significance 
was determined by One-way ANOVA followed by Tukey’s 
post-test and Two-way ANOVA followed by Sidak’s post-
test. P <  0.05 was considered significant. 
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